|
Herpes Simplex Infections
|
0.040 |
Biomarker
|
group |
BEFREE |
Serum antibodies to early proteins of human papillomavirus type 16 (HPV 16 E2 protein) and herpes simplex virus type 2 (HSV 2 ICP8) can be measured by ELISA.
|
1331306 |
1992 |
|
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
However, in contrast to cancer derived cell lines, immortalized cervical keratinocytes contained RNA with the potential to encode a full-length E2 protein.
|
1651587 |
1991 |
|
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
However, in contrast to cancer derived cell lines, immortalized cervical keratinocytes contained RNA with the potential to encode a full-length E2 protein.
|
1651587 |
1991 |
|
Papilloma
|
0.030 |
Biomarker
|
disease |
BEFREE |
The same DNA segment, that does not contain the consensus sequences of all papilloma viruses relevant for E2 protein-mediated transcription enhancement, functions in an enhancer-like fashion in addition to its glucocorticoid responsive action.
|
2828035 |
1987 |
|
Carcinoma
|
0.010 |
Biomarker
|
group |
BEFREE |
Hybridization with a probe specific for mRNA with a coding potential for a full-length E2 protein yielded weak signals in both carcinomas.
|
8386138 |
1993 |
|
Cervix carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Thus, a number of cervical carcinoma cell lines are remarkably sensitive to growth inhibition by the E2 protein.
|
8389903 |
1993 |
|
Male infertility
|
0.020 |
GeneticVariation
|
phenotype |
BEFREE |
Since heterozygous male mice and even knockout female mice are completely normal and fertile and thus able to transmit the defect, similar hHR6B mutations may cause male infertility in man.
|
8797826 |
1996 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using this E2 protein, the anti-E2 test was performed by EIA on 100 patients on maintenance hemodialysis, and on 50 patients with chronic hepatitis C who were anti-HCV-positive, to evaluate the antigenecity of the E2 protein.
|
8959633 |
1996 |
|
Hepatitis C, Chronic
|
0.010 |
Biomarker
|
disease |
BEFREE |
Using this E2 protein, the anti-E2 test was performed by EIA on 100 patients on maintenance hemodialysis, and on 50 patients with chronic hepatitis C who were anti-HCV-positive, to evaluate the antigenecity of the E2 protein.
|
8959633 |
1996 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Neutralization of HCV in vitro was attempted with a rabbit hyperimmune serum raised against a homologous synthetic peptide derived from the HVR1 of the E2 protein, and the residual infectivity was evaluated by inoculation of HCV-seronegative chimpanzees.
|
8986822 |
1996 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results indicate that antibody responses to predominantly conformational epitopes on the HCV E2 protein are common in patients with chronic HCV infection and are strictly related to the presence of circulating viral genomes.
|
8986942 |
1997 |
|
Rabies (disorder)
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Antibodies to the E2 region were sought for by ELISA using the following antigens: a full length E2 protein expressed in insect cells using a baculovirus vector and extracted under denaturing conditions (dE2), and a C-terminal truncated soluble E2 (sE2) protein (a.a. 390-683), also expressed with a baculovirus vector, containing a signal peptide of rabies virus G protein which allows its secretion into the culture supernatant.
|
8986942 |
1997 |
|
Viremia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Antibody responses to the hepatitis C virus E2 protein: relationship to viraemia and prevalence in anti-HCV seronegative subjects.
|
8986942 |
1997 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Purified HPV-16 E2 protein was used to develop enzyme-linked immunosorbent assays to detect serological IgG and IgA responses in cervical neoplasia patients and controls.
|
9099962 |
1997 |
|
Cervical Intraepithelial Neoplasia
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
We found that serum IgA levels against the E2 protein were elevated in CIN patients relative to normal control subjects but were not elevated in cervical cancer patients.
|
9099962 |
1997 |
|
Malignant neoplasm of skin
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
The sequence of the long control region (LCR) of Colobus monkey PV type 2 (CgPV-2) reveals a small size and an arrangement of potential cis-responsive elements typical of the EV-HPVs; namely four binding sites for the viral E2 protein, with one of them being located within the L1 gene, a cluster of nuclear factor I (NFI)- and AP-1-binding sites and a 50-bp sequence upstream of the E6 gene consisting only of the nucleotides A and T. This level of conservation of functional elements within the highly variable LCR suggests that CgPV-2 could be adopted as a model for studying human skin cancer associated with EV-HPVs.
|
9123827 |
1997 |
|
Viral hepatitis, type G
|
0.040 |
Biomarker
|
disease |
BEFREE |
Humoral immune response to the E2 protein of hepatitis G virus is associated with long-term recovery from infection and reveals a high frequency of hepatitis G virus exposure among healthy blood donors.
|
9398008 |
1997 |
|
Sexually Transmitted Diseases
|
0.010 |
GeneticVariation
|
group |
BEFREE |
To investigate the possibility of sexual transmission of GBV-C/HGV, we determined the frequency of viremia by the polymerase chain reaction and serological reactivity to the E2 protein by ELISA in samples collected from individuals at risk for sexually transmitted diseases attending a city genitourinary medicine clinic.
|
9624607 |
1998 |
|
Liver diseases
|
0.020 |
GeneticVariation
|
group |
BEFREE |
Although GBV-C is not yet associated with any cause of liver disease, a humoral immune response against the GBV-C envelope 2 (E2) protein has been observed.
|
9696000 |
1998 |
|
Viral hepatitis, type G
|
0.040 |
Biomarker
|
disease |
BEFREE |
Antibodies to E2 protein of hepatitis G virus in children: different responses according to age at infection.
|
9738721 |
1998 |
|
Viral hepatitis, type G
|
0.040 |
Biomarker
|
disease |
BEFREE |
Significance of antibodies to the recombinant E2 protein of hepatitis G virus in haemodialysis patients.
|
9795918 |
1998 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
While neither full length or C-terminally truncated variants of hepatitis C virus core protein nor hepatitis C virus E2 protein inhibited tumour necrosis factor alpha- or Fas antibody-induced apoptosis, a strong inhibition was observed with the cowpox virus cytokine response modifier A protein.
|
10583438 |
1999 |
|
Liver neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
This study investigated whether different variants of hepatitis C virus core or E2 protein interfere with tumour necrosis factor alpha or Fas (CD95/ APO-1) antibody-induced programmed cell death in transiently transfected human hepatoma (HepG2) cells.
|
10583438 |
1999 |
|
Liver carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
This study investigated whether different variants of hepatitis C virus core or E2 protein interfere with tumour necrosis factor alpha or Fas (CD95/ APO-1) antibody-induced programmed cell death in transiently transfected human hepatoma (HepG2) cells.
|
10583438 |
1999 |
|
Congenital infectious disease
|
0.010 |
Biomarker
|
group |
BEFREE |
The immune response against the recombinant E2 protein, however, was generally poor, but notably stronger after congenital infection.
|
10588454 |
1999 |